Followers | 4052 |
Posts | 152184 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
Wednesday, February 15, 2017 8:38:23 AM
FDA Exempts Evoke from Requirement for Human Factor Validation Study
SOLANA BEACH, Calif., Feb. 15, 2017-- Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that it has received a letter from FDA ...
FDA Exempts Evoke from Requirement for Human Factor Validation Study
GlobeNewswire•February 15, 2017Comment
SOLANA BEACH, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that it has received a letter from FDA exempting its late stage product, Gimoti™ from a Human Factors (HF) Validation study requirement prior to submission of a New Drug Application (NDA).
In February 2016, FDA published new guidance entitled “Applying Human Factors and Usability Engineering to Medical Devices”, which requires drug products classified as a drug/device combination, such as Gimoti, undergo evaluation that may require an HF Validation study as described in FDA’s Guidance.
To comply with this new Guidance, Evoke evaluated the need for an HF Validation study and submitted an HF assessment report to FDA for Gimoti using a Failure Mode and Effects Analysis risk analysis taking into account the intended uses, users, use environments, product-user interface, and associated medical factors. In their written response, FDA stated Evoke had adequately considered the risks associated with the proposed Gimoti nasal spray and determined that an HF Validation study is not needed at this time. The favorable FDA response helps reduce potential risks and saves additional resources in the development process including NDA preparation.
“We are very pleased with the continued FDA communication and their agreement that an HF Validation study is not needed. This is another step closer to a potential NDA submission which our entire team remains focused to deliver this year," commented Dave Gonyer R.Ph., President and CEO. Mr. Gonyer continued, “Given FDA agreement at a recent pre-NDA meeting to conduct a comparative exposure trial in healthy subjects, we are finalizing procedures to initiate that trial as soon as possible. We intend to pursue an NDA submission by the end of the year and plan to update our investors in the near term with more specific timelines on these efforts.”
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. Gimoti is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through nasal administration. Visit www.EvokePharma.com for more information.
Recent EVOK News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/27/2024 09:11:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 09:08:06 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 09/20/2024 11:28:39 PM
- Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments • GlobeNewswire Inc. • 09/19/2024 06:20:38 PM
- Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference • GlobeNewswire Inc. • 09/09/2024 12:30:08 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/09/2024 04:15:04 AM
- Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/04/2024 01:20:55 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/29/2024 08:16:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 11:00:08 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/13/2024 09:01:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:20:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 12:15:18 PM
- Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/13/2024 12:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 09:11:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:51:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:48:45 PM
- Evoke Pharma, Inc. Supports Gastroparesis Awareness Month • GlobeNewswire Inc. • 08/08/2024 12:30:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 11:00:09 AM
- Evoke Pharma, Inc. Announces Reverse Stock Split • GlobeNewswire Inc. • 07/30/2024 12:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 11:01:20 AM
- Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI • GlobeNewswire Inc. • 06/17/2024 12:30:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 12:00:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 09:02:13 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM